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inhibits growth and induces mitochondrial
apoptosis of lung cancer cells in vitro and
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Abstract
Background: 2,9-Bis[2-(pyrrolidin-1-yl)ethoxy]-6-{4-[2-(pyrrolidin-1-yl)ethoxy] phenyl}-11H-indeno[1,2-c]quinolin-11-
one (BPIQ) is a derivative from 6-arylindeno[1,2-c]quinoline. Our previous study showed the anti-cancer potential of
BPIQ compared to its two analogues topotecan and irinotecan. In the study, the aim is to investigate the potency
and the mechanism of BPIQ against lung cancer cells.
Methods: Both in vitro and zebrafish xenograft model were performed to examine the anti-lung cancer effect of
BPIQ. Flow cytometer-based assays were performed for detecting apoptosis and cell cycle distribution. Western blot
assay was used for detecting the changes of apoptotic and cell cycle-associated proteins. siRNA knockdown assay
was performed for confirming the apoptotic role of Bim.
Results: Both in vitro and zebrafish xenograft model demonstrated the anti-lung cancer effect of BPIQ. BPIQ-
induced proliferative inhibition of H1299 cells was achieved through the induction of G2/M-phase arrest and
apoptosis. The results of Western blot showed that BPIQ-induced G2/M-phase arrest was associated with a marked
decrease in the protein levels of cyclin B and cyclin-dependent kinase 1 (CDK1). The up-regulation of pro-apoptotic
Bad, Bim and down-regulation of pro-survival XIAP and survivin was observed following BPIQ treatment.
Conclusions: BPIQ-induced anti-lung cancer is involved in mitochondrial apoptosis. BPIQ could be a promising
anti-lung cancer drug for further applications.
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Background
Lung cancer is one of the leading malignancies world-
wide, and non-small cell lung cancer (NSCLC) accounts
for at least 80 % of lung cancer [1]. Approximately one
out of three patients with NSCLC has locally advanced
disease that is surgically unavailable [2]. Nowadays, che-
motherapeutic strategies for NSCLC therapy are con-
stantly developed and improved [2–6]. However, the
poor prognosis at an advanced stage of NSCLC and
chemotherapeutic resistance contribute to the low sur-
vival rate of NSCLC patients [3].
Quinoline ring was found in a variety of biologically ac-
tive compounds, which exert the anti-inflammation [7],
anti-autoimmunity [8] and anti-cancer proliferative activ-
ities [7, 9–12]. The well-known quinoline derivative,
camptothecin (CPT) is a pentacyclic quinoline isolated
from the Chinese tree Camptotheca acuminata, which
was reported to possess a potent cytotoxicity in a variety
of cancers (Fig. 1a). CPT derivatives including irinotecan
and topotecan are widely used as anti-cancer drugs [11].
However, the inherent chemical properties of CPT, includ-
ing poor solubility and instability under physiological con-
ditions, prevent its full clinical applications [13].
* Correspondence: cchiu@kmu.edu.tw; yeloch@kmu.edu.tw
1Department of Biotechnology, Kaohsiung Medical University, Kaohsiung 807,
Taiwan
2Department of Medicinal and Applied Chemistry, Kaohsiung Medical
University, Kaohsiung 807, Taiwan
Full list of author information is available at the end of the article
© 2015 Chiu et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Chiu et al. BMC Cancer  (2015) 15:962 
DOI 10.1186/s12885-015-1970-x
Accordingly, the quinoline derivatives are being developed
to enhance the anti-tumor activity and reduce side effects
[14, 15]. Subsequent introduction of hydrophilic side
chains led to the discovery of topotecan and irinotecan
which are currently used as anti-cancer drugs [11].
To overcome these aforementioned limitations and
to improve the therapeutic potential of quinoline de-
rivative, we synthesized a novel 2,9-bis[2-(pyrrolidin-
1-yl)ethoxy]-6-{4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}-11
H-indeno[1,2-c]quinolin-11-one (BPIQ) [9, 11, 16].
Further, the previous study has demonstrated the
anti-proliferation potential of BPIQ in several cancer
cells, including NSCLC and hepatocellular carcinoma
(HCC) tumor cells [9, 11]. Interestingly, the previous
work showed that BPIQ exerts more strong toxicity
towards lung cancer cell lines compared to other two
BPIQ analogues, topotecan and irinotecan, which
were used as anti-cancer drugs [17].
Despite the potent inhibitory effect of BPIQ on prolif-
eration of NSCLC cancer cells, little is known about its
underlying mechanism. To clarify the proliferation in-
hibition by BPIQ, cellular and molecular parameters per-
taining to BPIQ-induced apoptosis were studied using
three NSCLC tumor cells, H1299, H1437 and A549. In
addition to the in vitro assays, we also performed the
zebrafish xenograft to evaluate the anti-cancer potential
of BPIQ, as well as its toxicity towards zebrafish larvae
as the side-effect index.
Methods
Preparation of BPIQ and CPT
BPIQ (Fig. 1a) was synthesized as previously described
[9, 11]. Camptothecin (CPT) was purchase from Sigma-
Aldrich (St. Louis, MO, USA). Both BPIQ and CPT were
dissolved in DMSO (less than 0.01 %) immediately prior
to experiments.
Reagents
The following compounds were obtained from Gibco BRL
(Gaithersburg, MD, USA): DMEM medium, fetal bovine
serum (FBS), trypan blue, penicillin G, and streptomycin.
Dimethyl sulphoxide (DMSO), CPT, ribonuclease A
(RNase A), and propidium iodide (PI) were purchased
from Sigma-Aldrich. Antibodies against Bcl-2, XIAP, sur-
vivin, cytochrome c, Bax, Bad, PARP, and β-actin were ob-
tained from Santa Cruz Biotechnology (Santa Cruz, CA,
USA). Antibodies against cleaved caspase-3 and caspase-9
were purchased from Anaspec (San Jose, CA, USA). Anti-
mouse and anti-rabbit IgG peroxidase-conjugated second-
ary antibodies were purchased from Pierce (Rockford, IL,
USA). The anti-rabbit Rhodamine-conjugated antibody
was purchased from Abcam (Cambridge, UK). Annexin
V-Fluorescein isothiocyanate (FITC) staining kit was pur-
chased from Strong Biotech (Taipei, Taiwan). The cationic
cyanine dye, carbonyl cyanide 3-chlorophenylhydrazone
(CCCP) included in DiOC2(3) assay kit was obtained from
Invitrogen (Carlsbad, CA, USA).
Fig. 1 Effect of BPIQ on proliferation of NSCLC tumor cells. a The structures of CPT and BPIQ. b Three NSCLC H1299, A549 and H1437 cells were
incubated with various concentrations of BPIQ for 24 and 48 h, respectively. The percentage of viable cells was calculated as a ratio of BPIQ- to
DMSO-treated control cells. c The tumor volume in the zebrafish xenograft model. The intensity of red fluorescence is proportional to the
xenograft tumor size. N = 20 embryos for each group. d The quantificative analysis of c. All data are presented as mean ± S.D. of three independent
experiments. (*p < 0.05, **p < 0.005 and ***p < 0.001 against vehicle control, respectively)
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Cell culture
Human non-small cell lung cancer (NSCLC) cells
H1299, H1437 and A549 were obtained from the
American Type Culture Collection (ATCC; Manassas,
VA, USA). All tested cells were maintained in
DMEM: F-12/3:2 ratio and supplemented with 8 %
FBS, 2 mM glutamine, and antibiotics (100 units/ml
penicillin and 100 μg/ml streptomycin) at 37 °C in a
humidified atmosphere of 5 % CO2. Before all assays
performed in the study, all cells were tested to ex-
clude the mycoplasma contamination using a PCR-
based assay described by Wirth et al. [18].
Proliferative inhibition assay
The cell proliferation rate and cell viability were deter-
mined by trypan blue dye exclusion assay combined with
the Countess™ automated cell counter performed ac-
cording to the manufacturer’s instruction (Invitrogen,
Carlsbad, CA, USA). Briefly, 1 × 105 cells were seeded
and treated with DMSO as vehicle or the indicated con-
centrations of BPIQ for 24 h and 48 h. After incubation,
cells were exposed to 0.2 % trypan blue and counted by
Countess™ [19].
Apoptosis assessment
To examine the apoptosis-inducing potential of BPIQ,
Annexin-V/PI double staining was performed to detect
the externalization of phosphatidylserine (PS). In brief,
5 × 105 cells were seeded onto 100-mm petri dishes and
treated with or without BPIQ for 24 h. Subsequently,
cells were harvested and stained with Annexin V staining
kit according to the manufacturer’s manual. Cells were
analyzed by flow cytometry (FACS Calibur; Becton
Dickinson, Mountain View, CA, USA) using WinMDI
2.9 software (written by Joseph Trotter, Scripps Research
Institute, La Jolla, CA, USA).
Mitochondria membrane potential (MMP) analysis
The changes of MMP were measured by flow cytometry
using DiOC2(3) fluorescence dye following the manufac-
turer’s instructions. Cells were treated with 50 μM of
carbonyl cyanide 3-chlorophenylhydrazone (CCCP) as a
positive control. Data were analyzed using the CellQuest
software (Becton Dickinson).
Cytosolic extraction for Western blot
To determine whether BPIQ causes cytochrome c
release, a protein extraction of cytosol fraction was con-
ducted by the mitochondria protein extraction kit Bio-
PMTF-60 (BioKit, Hsinchu, Taiwan). Briefly, a total of
5 × 106 cells was harvested by centrifugation. Cell pellet
was resuspended in reagent A and vortexed, then incu-
bated on ice. The lysates were centrifuged to collect su-
pernatants as cytosolic fraction and transfer to a fresh
tube and added reagent B to each precipitation part, vor-
tex for homogeneous solution and centrifugation. Fi-
nally, the cytosolic fractions were further analyzed by
Western blotting.
Western blot analysis
Western blotting was performed as described previously
[20]. Briefly, cells were harvested and lysed. Lysates were
centrifuged, and the protein concentration was deter-
mined. Equal amounts of protein were separated by SDS-
polyacrylamide gel electrophoresis (SDS-PAGE) and then
electrotransferred. The membrane was blocked with 5 %
non-fat milk, followed by incubation with primary and
secondary antibodies against specific proteins. The signals
were detected using enhanced chemiluminescence (ECL)
detection kit (Amersham Piscataway, NJ, USA).
Immunofluorescence assay
To determine whether BPIQ causes the release of cyto-
chrome c, the immunofluorescence assay was con-
ducted according to a previous study with minor
modifications [1]. In brief, H1299 and A549 cells were
grown on 12-mm glass coverslips (Marienfeld Labora-
tory, Lauda-Königshofen, Germany) respectively. Cells
treated with BPIQ were attached using 37 % nitric acid
(Sigma-Aldrich), fixed with 4 % paraformaldehyde and
permeabilized with 0.5 % Tween-20. Cells were incu-
bated overnight at 4 °C with the primary antibody
against cytochrome c (#sc13156, Santa Cruz Biotech-
nology), washed with 1 % Bovine serum albumin (BSA),
the incubated with Alexa Fluor 555–conjugated goat
anti–mouse immunoglobulin G (#A21422, Molecular
Probes, Invitrogen, Carlsbad, CA). The slides were
mounted in fluorescent mounting medium Vectashield
H-1000 (Vector Laboratories, Burlingame, CA, USA).
siRNA knockdown assay
Bim siRNA (Hs_BCL2L11) was purchased from Bertec,
Taiwan. Bim siRNA or a scrambled sequence control
was transfected into H1299 cells using the transfection
reagent RNAi Lipofectamine according to the manufac-
ture instruction (Invitrogen, Life Technologies, Carlsbad,
CA, USA). After 24 h of transfection, the medium was
refreshed, and the cells were incubated at 37 °C with a
humidified atmosphere of 5 % CO2 for an additional
24 h [1].
Zebrafish xenograft assay
The zebrafish (Danio rerio) Tg(fli1:EGFP) were obtained
from Taiwan
Zebrafish Core Facility at Academia Sinica (TZCAS,
Taipei, Taiwan). The care and maintenance of zebrafish
were handled in compliance with the animal care regula-
tions and standard protocols of the animal center
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(Kaohsiung Medical University Hospital, Kaohsiung,
Taiwan) for zebrafish adults and larvae). Zebrafish were
kept at 28.5 °C in aquaria with day/night light cycles
(10 h dark vs. 14 h light periods).
Zebrafish xenograft assay
The zebrafish xenograft assay was used for confirming
the inihibitory effect of BPIQ on proliferation of lung
cancer cells. The use of zebrafish complied with the
principles of 3Rs (Reduction, Replacement and Refine-
ment) and the approval protocol (IACUC Approval
No. KMU-IACUC-102033) by Institutional Animal
Care and Use Committee (IACUC) of Kaohsiung
Medical University Hospital, Kaohsiung, Taiwan We
transfected a red fluorescent protein from pDsRed-
Express-C1 (Clontech, Mountain View, CA, USA) into
human lung tumor cells for tracking in the zebrafish
xenograft model with a fluorescence microscopy. The
procedure was performed according to a previous
study with minor modifications [20]. Briefly, 48 h
post-fertilization (hpf ) zebrafish embryos were anes-
thetized with 0.01 % of tricaine and transplanted with
about 50 lung cancer cells per embryo. Cells then
were resuspended in Hanks balanced salt solution and
injected into the yolk sac of the embryos. The em-
bryos were incubated in water at indicated concentra-
tions of BPIQ for 24 and 48 h post-injection (hpi),
respectively. Afterwards, photographs of embryos were
taken by an inverted microscope (Nikon Eclipse
TE2000-U, Tokyo, Japan).
Statistical analysis
Differences between BPIQ- and DMSO- (as vehicle con-
trol) treated cells were analyzed in at least triplicate ex-
periments. The significance of the differences was
analyzed by one-way analysis of variance (ANOVA), with
p < 0.05 considered significantly.
Results
BPIQ exerts the anti-lung cancer potential both in vitro
and in vivo
To examine the effect of BPIQ on cell growth, three
NSCLC tumor cell lines H1299 (null p53), A549 (wild
type p53) and H1437 (mutant p53-R267P) were treated
with increasing concentrations of BPIQ for 24 h and
48 h. Cell survival was assessed by trypan blue exclusion
combined with an automated cell counter. As shown in
Fig. 1b, significant inhibition of proliferation was de-
tected at 1, 2, 5 and 10 μM BPIQ in both dose- and
time-dependent manners. Both the IC50 of BPIQ and
CPT at 24 h and 48 h for three NSCLC cell lines are
shown for comparison in Tables 1 and 2 (The prolifera-
tion inhibition curve for CPT is shown in the Additional
file 1: Figure S1). We further examined whether BPIQ
inhibits the growth of NSCLC cells in vivo. H1299 cells,
the most invasive among three tested NSCLC cells, were
implanted into the yolk sac of zebrafish larvae for 72 h
followed by incubating larvae with different BPIQ con-
centrations for the indicated times. Consistently, the
zebrafish xenograft assay further confirmed the anti-lung
cancer potential of BPIQ (Fig. 1c and d) in that the ob-
served tumor sizes, as indicated by the intensity of red
fluorescence, were reversely proportional to BPIQ con-
centrations in zebrafish larvae.
BPIQ causes G2/M arrest and aberrant polyploidy in
H1299 cells
As shown in Fig. 2a and b, the G2/M population per-
centiles of H1299 cells treated with vehicle control
and various BPIQ concentrations (1, 2, 5 and 10 μM)
were 24.7 ± 0.3, 25.19 ± 0.5, 27.76 ± 0.5, 37.18 ± 0.4,
and 41.61 ± 0.1 (n = 3), respectively. BPIQ induced ac-
cumulation of G2/M population of H1299 lung cancer
cells increased in a dose dependent manner (Fig. 2c).
Additionally, the BPIQ-induced polyploidy population
(>4 N DNA) was slightly increased at a dose of 1 μM
(p < 0.05) compared to untreated cells and became
more significantly increased at the higher doses of 2,
5 and 10 μM (p < 0.0001) (Fig. 2d). Furthermore, the
decreased protein levels of G2/M effectors cdk1 and
cyclin B were also observed in a dose-dependent
manner (Fig. 2e).
Apoptosis was triggered by BPIQ in H1299 cells efficiently
To determine whether BPIQ inhibits cell survival by in-
ducing apoptosis, the flow cytometry based- Annexin V/
PI dual staining was performed. H1299 cells cultured
with different concentrations of BPIQ for 24 h were
stained with Annexin V/PI to detect the externalization
of PS from the cell membrane. In this assay, Annexin V
−/PI− cells were considered healthy, Annexin V−/PI+
Table 1 The comparison of CPT and BPIQ on anti-lung cancer
activity. a IC50 values for BPIQ-treated NSCLC cells
Cell line (IC50 of BPIQ,μM)
Time H1299 H1437 A549
24 h 1.96 0.89 1.78
48 h 1.30 0.93 0.75
Table 2 The comparison of CPT and BPIQ on anti-lung cancer
activity. b IC50 values for CPT-treated NSCLC cells
Cell line (IC50 of CPT,μM)
Time H1299 H1437 A549
24 h 2.73 N.D. 3.20
48 h 1.60 N.D. 1.55
N.D. Not determined
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cells were considered necrotic, Annexin V+/PI− cells
were considered early apoptotic, and Annexin V+/PI+
cells were considered late apoptotic. After treatment
with vehicle control or 1, 2, 5 and 10 μM of BPIQ for
24 h, the cells displayed early- and late-stage of apop-
tosis as shown in Fig. 3. BPIQ caused a dose-dependent
increase in the percentage of both early and late apop-
totic cells (Fig. 3a and b), and the apoptosis-promoting
capacity of BPIQ was significant at either 5 or 10 μM
(Fig. 3c). These results showed that BPIQ efficiently in-
duced apoptosis of H1299, suggesting that BPIQ inhib-
ited proliferation of H1299 cells through induction of
apoptosis.
BPIQ induces the disruption of MMP and mitochondrial-
mediated apoptosis
As depicted in Fig. 4a, BPIQ induced disruption of
MMP. Furthermore, Fig. 4b showed the quantitative
Fig. 2 BPIQ induced an accumulated G2/M population and aberrant polyploidy in H1299 cells. Cells were treated with the indicated doses
(vehicle control, 1, 2, 5, and 10 μM) of BPIQ for 24 h, respectively. a The accumulation of the G2/M population in BPIQ-treated H1299 cells and
vehicle controls at 24 h. b The quantification analysis of cell cycle distribution. Different letter notations indicate the statistical significance
between BPIQ treatment and vehicle (a vs. b and a vs. c indicate the p < 0.005 and p < 0.001, respectively.). c Analysis of G2/M population.
d Analysis of polyploidy. Data are presented as means ± S.D. (n = 3). Different letter notations indicate the statistical significance between drug
treatment and vehicle (*p < 0.05 and **p < 0.001 respectively). e Western blot analysis demonstrating BPIQ-induced down-regulation of CDK1 and
cyclin B protein levels. β-actin was measured as an internal control
Fig. 3 BPIQ induced apoptosis of H1299 cells. a Cells cultured with different concentrations of BPIQ for 24 h were stained with Annexin V/PI to
detect externalization of PS from cell membrane. b Quantitative analysis of Annexin V staining. c Quantitative analysis of apoptotic cells. Different
letter notations indicate the statistical significance between BPIQ treatment and vehicle (a vs. b and a vs. c indicate the p < 0.005 and
p < 0.001, respectively.)
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values. The MMP changes (Δψm) induced by various
BPIQ concentrations were 14.14 ± 0.22 (vehicle control),
17.69 ± 0.58 (1 μM), 19.92 ± 0.13 (2 μM), 25.06 ± 2.16
(5 μM), 55.04 ± 1.09 (10 μM), respectively. Additionally,
the MMP change in cells treated with CCCP (50 μM) as
positive control was 36.72 ± 0.7. These results suggested
that BPIQ potentially triggers the disruption of MMP,
the hallmark of mitochondrial mediated apoptosis in a
dose-dependent manner. Furthermore, other major hall-
marks of apoptosis, including the release of cytochrome
c, cleaved caspase-9 and −3, as well as cleaved form of
PARP were detected at higher BPIQ concentrations used
(Fig. 4c, lanes 4 and 5). Likewise, the immunofluores-
cence assay showed that the BPIQ causes the redistribu-
tion of cytochrome c into the cytosol of H1299 cells
(Fig. 4d. The yellow fluorescence indicates the colocali-
zation of cytochrome c and mitochondria, and the red
fluorescence indicates the distribution of cytochrome c).
BPIQ disturbs the balance of pro-survival and pro-
apoptosis Bcl-2 family proteins
To examine the effects of BPIQ treatment on protein
levels involved in apoptosis, H1299 cells were treated
with various concentrations of BPIQ for 24 h before cell
lysates were harvested and subjected to Western blot
analyses. As shown in Fig. 5a, BPIQ significantly de-
creased the levels of pro-survival proteins survivin and
XIAP, whereas no significant changes of Bcl-2 protein
were observed. On the contrary, the levels of two pro-
apoptotic proteins, Bim and Bad, were dramatically in-
creased following BPIQ treatment in a dose-dependent
manner (Fig. 5b). Figure 5c showed the protein level
changes of survivin, XIAP and Bad in BPIQ-treated
H1299 cells in a time-course manner. Furthermore, the
knockdown assay confirmed the pro-apoptotic role of
Bim in BPIQ-induced apoptosis of H1299 cells (Fig. 5d).
Discussion
Due to the poor prognosis in advanced human
NSCLC tumors, screening compounds which select-
ively exhibit apoptosis-inducing capability is the ur-
gent goal for NSCLC chemotherapy. Our previous
study showed that the synthetic quinoline derivative
BPIQ is an anti-growth agent against lung cancer and
liver tumor cells [9, 11]. The values of 50 % growth
inhibition (GI50) of the topotecan- and irinotecan-
Fig. 4 Loss of MMP and caspase activation by BPIQ. a H1299 cells were exposed to media containing the indicated concentrations of BPIQ or
vehicle control for 24 h, stained with DiOC2(3), then analyzed for changes in their fluorescent profile by flow cytometry. b Quantitative analysis.
Data are presented as means ± S.D. Histograms represent one of three independent experiments. *p < 0.05 and **p < 0.001 against vehicle
control, respectively. c Western blot analysis demonstrating BPIQ-induced cytochrome c release and cleavage of caspase-9 and −3, as well as
PARP. β-actin was measured as an internal control. d The distribution of cytochrome c in the cytosol of two NSCLC cell lines A549 and H1299
following 2 μM BPIQ treatment. ▪ mitochondria; ▪ cytochrome c; ▪ DAPI; ▪ co-localization of mitochondria and cytochrome c. Magnification 200 x
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treated A549 lung cancer cells at 24 h were 5.98 ±
0.26 μM and > 10 μM respectively. Likewise, both the
GI50 values of the topotecan- and irinotecan-treated
H1299, an invasive lung cancer cells at 24 h were
higher than >10 μM. In comparison of the CPT ana-
logues, our previous results showed that BPIQ ex-
hibits a significantly cytotoxicity against both NSCLC
cells lines at 24 h (GI50, 0.67 ± 0.01 μM and 0.37 ±
0.07 μM, respectively) (compound 15 as BPIQ in
Table 1.) [9, 11].
To evaluate the efficacy of CPT and BPIQ on sup-
pressing growth of lung cancer cells, the proliferation
assay was also conducted. The results showed that IC50
of CPT for H1299 cells was 2.73 (24 h) and 1.6 μM
(48 h), respectively, and the IC50 of CPT for A549 cells
was 3.20 (24 h) and 1.55 μM (48 h), respectively
(Additional file 1: Figure S1). These results suggest that
the inhibitory efficacy of BPIQ is moderately better than
CPT. The safety of BPIQ for clinical applications should
be worthy for evaluating in our further in vivo study.
Accordingly, in this study, we further demonstrated
the anti-proliferative effect of BPIQ on human
NSCLC cells, including H1299, H1435, as well as
H1437. The results confirmed that BPIQ effectively
inhibited the proliferation of all tested NSCLC tumor
cells (Fig. 1b and c).
Because of the advantages of small size, embryonic
transparency and rapid development, zebrafish (Danio
rerio) is widely used as an ideal model organism [21, 22].
Furthermore, the physiological responses in zebrafish to
tested compounds can be comparable to those in mam-
malian models [22]. Recently, zebrafish xenograft assay
is becoming a useful tool for investigating and tracking
human cancer cells in zebrafish larvae, such as invasion,
tumor proliferation [23] and angiogenesis [24]. The
transparency of zebrafish embryos and larvae makes the
Fig. 5 The effects of BPIQ on modulation of Bcl-2 family members in H1299 cells. Cells were subjected to treatment with vehicle control or the
indicated doses of BPIQ. a Western blot showed the significantly decreased levels of IAP factors survivin and XIAP. b Western blot showed the
increase in pro-apoptotic Bid, Bad and Bim protein levels. c Western blot showed BPIQ causes the changes of IAP factors and pro-apoptotic Bad
in a time dependent-manner. β-actin was measured as an internal control. Each blot is representative of three independent experiments. d The
effect of Bim knockdown on BPIQ-induced apoptosis of H1299 cells determined using a cytometry-based annexin v staining assay. *p < 0.05 for
scramble siRNA versus. Bim siRNA
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xenograft assay to be readily performed for observing
tumor proliferation and interactions between cancer
cells and the microenvironment in zebrafish. Import-
antly, the zebrafish xenograft assay can evaluate both the
activity and side effect of a tested compound [9, 11].
Therefore, to further validate the anti-lung cancer effects
of BPIQ, we conducted the zebrafish xenograft assay.
Consistently, the results of zebrafish xenograft assay
showed the inhibitory effect of BPIQ on lung cancer
cells. However, we also found that the highest dose
(5 μM) of BPIQ caused a significantly toxicity towards
zebrafish larvae (data not shown), suggesting that the
dose usage of BPIQ should be more careful when further
applied for lung cancer chemotherapeutics. Nevertheless,
these observations indicate that BPIQ may have the po-
tential for lung cancer treatment in the future.
To uncover the molecular mechanism of BPIQ-
mediated inhibition on NSCLC cells proliferation, we ex-
amined the effect of BPIQ on cell cycle distribution of
H1299 cells. The cell cycle analysis showed that BPIQ
induced a moderate accumulation of G2/M population
(Fig. 2a), which was accompanied by polyploidy (>4n)
(Fig. 2b and d). Recent studies showed that certain anti-
cancer drugs exert their effects through destabilizing the
genome and causing aberrant polyploidy. For example,
the aurora B kinase inhibitor ADZ1522 causes an in-
creased proportion of polyploidy cells [25] and apoptotic
cell death of colorectal cancer cells SW620 [13]. More-
over, doxorubicin could induce genome instability and
polyploidy and cause the senescence of HCT116 colon
cancer cells [26]. Consistently, we found that BPIQ
caused significant accumulation of G2/M population and
the aberrant polyploidy. Furthermore, the CDK1-cyclin
B1 complex regulates entry of cell cycle into mitosis,
and the decreased levels or loss of activities of cyclin B1
and CDK1 causes the G2/M arrest and may promote
apoptotic cell death [27, 28]. Our current study showed
that protein levels of CDK1 and cyclin B1 were dramat-
ically decreased by BPIQ treatments. These observations
suggest that BPIQ-induced growth inhibition is associ-
ated with G2/M arrest and the aberration of polyploidy.
Annexin V/PI double staining showed that BPIQ sig-
nificantly induced apoptotic cell death, and caused pro-
teolytic activation of caspase-3 and −9, as well as
proteolytic inactivation of PARP (Fig. 3). Since BPIQ in-
duced the disturbance of MMP and the release of cyto-
chrome c, we suggest that BPIQ-induced apoptosis of
H1299 cells is mitochondria-mediated (Fig. 4a and b).
Numerous studies suggest that mitochondria play
an important role in cell survival and cytochrome c-
mediated apoptosis by modulating the balance of pro-
apoptotic and anti-apoptotic Bcl-2 family proteins
[29–31]. For example, anthocyanin, a member of the
flavonoid family, induces apoptosis of leukemia U937
cells by down-regulating Bcl-2 expression [32]. On
the contrary, up-regulation of pro-apoptotic protein
Bim was observed in glucocorticoid-induced apoptosis
of acute lymphoblastic leukemia CEM cells [33]; and
matrine, a sophora alkaloid, induced cell death of
colorectal cancer through up-regulating bad expres-
sion [34]. Additionally, the inhibitors of apoptosis
proteins (IAPs) also play important roles in negative
regulation of apoptosis [35, 36]. Our result showed
that BPIQ treatment increased protein levels of pro-
apoptotic Bim and Bad, and this may disturb the
balance of Bcl-2 family proteins. Additionally, dramat-
ically decreased levels of two IAP proteins, survivin
and XIAP, were detected (Fig. 5a and b). These obser-
vations are consistent with previous studies that in-
creased levels of pro-apoptotic proteins induce
cellular apoptosis [37, 38].
To further determine whether BPIQ could disturb
the balance between pro-survival Bcl-2 protein and
the endogenous inhibitors such as XIAP and survivin
factor and pro-apoptotic Bcl-2 proteins in a time-
dependent manner, expression levels of several Bcl-2
family proteins were determined using a time-course
experiment. As shown in Fig. 5c, the results of
Western blot showed that the levels of pro-survival
IAP proteins, including XIAP and survivin, were de-
creased at 16 and 24 hr, respectively, following BPIQ
treatment. On the contrary, the protein level of Bad
was dramatically increased at 24 h, suggesting BPIQ-
induced a disturbance of anti-apoptosis and pro-
apoptosis Bcl-2 family in a time-dependent manner.
To validate whether the up-regulation of Bim is in-
volved in BPIQ-induced apoptosis, we also performed
the knockdown experiments. The results of Annexin
V-assay showed that Bim knockdown protects H1299
cells from undergoing apoptosis induced by BPIQ
(*p > 0.05). Although apoptosis-inducing dose (5 μM)
of BPIQ causes a significant increased level of Bim,
the Annexin V staining assay showed that blockage of
Bim partially rescues H1299 cells from BPIQ-induced
apoptosis. The may due to the efficiency of siRNA
transfection, and we suggest that Bim knockout may
improve the rescues of BPIQ-induced apoptosis.
Nevertheless, our results demonstrate the involvement
of Bim in mediating BPIQ-induced apoptosis of
H1299 cells.
The induction of apoptosis can initiate through two
distinct pathways: the intrinsic apoptotic and the extrin-
sic apoptotic pathways [39]. Therefore, we also examined
whether the extrinsic apoptotic pathway (death receptor-
pathway) is also activated by BPIQ treatment, and the
preliminary results of Western blot showed that no
significant changes of caspase-8, a key caspase of the ex-
trinsic apoptotic pathway was observed (data not
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shown). However, we still can not exclude the possibility
that other extrinsic death pathway, such as caspase-10,
coordinately involves BPIQ-induced apoptosis. Accord-
ingly, our present results suggest that BPIQ induces
apoptosis of lung cancer H1299 cells through
mitochondria-mediated, an intrinsic pathway.
Conclusion
Our present work suggests that BPIQ exerts the anti-
lung cancer cells both in vitro and in vivo. BPIQ-
induced apoptosis was accompanied by perturbing the
balance of pro- and anti-apoptotic Bcl-2 proteins by
down-regulating levels of survivin and the IAP
protein XIAP, and up-regulating levels of two pro-
apoptotic proteins, Bim and Bad (Fig. 6). Our study
sheds a light on the mechanism of BPIQ-based
NSCLC chemotherapy.
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